Award Number: W81XWH-07-1-0651

TITLE: Can Diabetes Change the Intrinsic Subtype Specificity of Breast Cancer?

PRINCIPAL INVESTIGATOR:
Harikrishna Nakshatri, B.V.Sc., PhD
Kasi R. McCune, MD

CONTRACTING ORGANIZATION:
Indiana University
Indianapolis, In 46202

REPORT DATE: September 2008

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:
Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Can Diabetes Change the Intrinsic Subtype Specificity of Breast Cancer

**Abstract**

Luminal type A and type B breast cancers represent estrogen receptor alpha (ERα)-positive breast cancers with luminal type A associated with better prognosis. A transcription factor network comprising GATA-3, FOXA1 and ERα dictates estrogen (E2) dependence of luminal type A breast cancer. Signaling molecules that disrupt this network may play a role in E2-independence. T-bet is a major negative regulator of GATA-3. As the expression of some of the above factors are controlled by insulin, the objective of this study was to investigate the ability of insulin, as in type II diabetes, to disrupt GATA-3:FOXA1:ERα network. Insulin induced the expression of T-bet in MCF-7 breast cancer cells and MCF-7 cells engineered to overexpress T-bet (MCF-7-T-bet) were anti-estrogen resistant in the presence of insulin. E2-inducible expression of XBP-1, an ERα:FOXA1:GATA3 downstream target, was attenuated in MCF-7-T-bet cells compared to parental cells suggesting disruption of this hormonal network by T-bet. MCF-7 cells that have acquired resistance to anti-estrogens overexpressed T-bet and expressed lower levels of FOXA1 compared to parental cells. Importantly, Oncomine database search revealed T-bet overexpression in a subgroup of ERα-positive breast cancers, suggesting a role for T-bet in modulating ERα activity in a subset of ERα-positive breast cancers. MCF-7-xenograft studies with or without experimentally induced diabetes are currently underway to recapitulate in vitro observations in an in vivo setting.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4-6</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>6</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>6-7</td>
</tr>
<tr>
<td>Conclusion</td>
<td>7</td>
</tr>
<tr>
<td>References</td>
<td>7-8</td>
</tr>
<tr>
<td>Appendices</td>
<td>9-15</td>
</tr>
</tbody>
</table>
**Introduction:** Breast cancer has been classified into five intrinsic subtypes with variable prognostic significance based on gene expression profiling studies: Luminal type A (good prognosis), Luminal type B, Her2-positive, Normal-like and Basal-type (worst prognosis group) (1). Luminal type A breast cancers differ from Luminal type B with respect to levels/activity of estrogen receptor alpha (ERα) and possibly on their dependency on estrogen for survival (1). In addition, another transcription factor called FOXA1 modulates the function of ERα and is specifically expressed at higher levels in Luminal type A cancers (2, 3). Higher FOXA1 expression associated with good prognosis, a characteristic similar to Luminal A cancers (3). As FOXA1 expression and activity are negatively regulated by Insulin and tumor necrosis factor (TNF), respectively (4), the question is whether metabolic/stress disorders unrelated to breast cancers that lead to elevated serum Insulin and TNF alter the function of ERα:Estrogen:FOXA1 network and thus promote progression of Luminal type A cancers from hormone-dependent to hormone-independent phenotype or to Luminal type B subtype.

A network comprising ERα, estrogen, FOXA1 and GATA-3 constitutes a major morphogenesis and differentiation pathway involving luminal cells of normal breast and is a critical hormonal signaling network in Luminal type A breast cancer (1, 5, 6). In fact, ERα:FOXA1:GATA3 transcription factor network has been dubbed as a cell lineage enriched hormonal network in breast cancer (7). While ERα:estrogen axis has been the major focus of investigation, how metabolic/stress conditions that alter the expression/activity of FOXA1 and GATA-3 change the biology of Luminal type A breast cancers is not known. Our hypothesis is that in breast cancer patients who develop diabetes subsequent to their initial diagnosis of having Luminal type A breast cancers, recurrent tumors may not retain gene expression pattern of Luminal type A subtype because of the effects of Insulin or TNF on FOXA1 expression/activity. As a consequence, ERα:estrogen:FOXA1:GATA-3 network may not be the major signaling network in recurrent tumors and is replaced by ERα-independent proliferation/survival pathway.

**Body:**

**Objective:** Investigate whether Luminal type A breast cancer cell line MCF-7 implanted into nude mice with experimentally induced type I diabetes (no Insulin but hyperglycemia) or type II diabetes (elevated serum Insulin and hyperglycemia) progress to become Luminal type B or any other intrinsic subtype.

**Progress on in vitro studies to identify targets of Insulin that may disrupt hormonal network:**

**T-bet is overexpressed in a subset of ERα-positive breast cancers:** GATA-3 was originally characterized as a signaling molecule involved in T cell differentiation (8). Subsequent studies have shown similar role for GATA-3 in differentiation of luminal progenitor cells of the breast (6). T-bet, also called Tbx21, is a negative regulator of GATA-3 activity in T cells (8). Furthermore, T-bet is expressed in the epithelial cells of the endometrium; expression of both GATA-3 and T-bet cyclical in these cells suggesting hormonal regulation of their expression (9). Therefore, we considered the possibility of T-bet regulating GATA-3 activity in breast cancer cells and disrupting GATA-3, FOXA1 and ERα-regulated hormonal network.
The Oncomine database was utilized to determine a correlation between T-bet and ERα expression in primary breast cancer. Although T-bet is expressed at higher levels in ERα-negative breast cancers compared to ERα-positive breast cancers, a subset of ERα-positive breast cancers expressed higher levels of T-bet (Figure 1). T-bet expression was also associated with progesterone receptor (PR) negativity, a subgroup that is known for being resistant to endocrine therapy. This begs the question whether T-bet positivity could be related to endocrine insensitivity in ERα positive tumors.

**Insulin induces T-bet expression in breast cancer cells:** To determine whether T-bet is expressed in breast cancer cell lines and the expression is regulated extracellular signals, we investigated the effects of growth hormone, Insulin, Insulin-like growth factor II, and estrogen on T-bet expression in MCF-7 cells. Insulin but not other factors induced T-bet expression (Figure 2A).

We next examined the effects of Insulin on GATA3 and FOXA1 expression. If crosstalk between T-bet and GATA3 is similar in both T cells and breast epithelial cells, Insulin is expected to reduce the expression and/or activity of GATA3. Consequently, FOXA1 expression should be low in Insulin-treated cells. As expected, Insulin reduced the expression of GATA3 but failed to have significant effect on the expression of FOXA1 (Figure 2B). These results suggest that Insulin-induced T-bet significantly effects GATA3 expression. Unlike in normal mammary gland, FOXA1 expression in cancer cells may be independent of GATA3.

Additional ERα-positive breast cancer cell lines were examined for basal and Insulin-regulated expression of T-bet. T-bet expression was markedly higher in BT-474 cells, which is considered as luminal type B cell line (Figure 2C). GATA3 in not expressed in these cells; however, FOXA1 is expressed at high level suggesting GATA3 independent expression of FOXA1 in these cells. T47-D cells also express T-bet; however, unlike MCF-7 cells, T-bet expression was not regulated by Insulin. Taken together, these results reveal an association between T-bet and GATA3 expression in breast cancer cells and cell type-specific effects of Insulin in modulating their expression.

**T-bet overexpression in MCF-7 cells leads to altered estrogen and tamoxifen response:** To determine whether T-bet negatively regulates estrogen-inducible expression of specific ERα, GATA3 and FOXA1 target genes, we generated MCF-7 cells overexpressing T-bet (Figure 3A). XBP1 has been suggested as the downstream target of ERα, FOXA1 and GATA3 network as meta-analysis has revealed coexpression of all four of these genes in a significant proportion of breast cancer (10). Binding sites for all three transcription factors are also present in the regulatory region of XBP-1 (2). While XBP-1 expression was readily estrogen-inducible in parental cells, estrogen failed to induce the expression of XBP-1 in T-bet overexpressing cells (Figure 3B). The effect of T-bet on estrogen-inducible expression is gene-specific because estrogen induced Myb and Cyp19 to similar levels in parental and T-bet overexpressing cells.

**T-bet overexpressing cells are less sensitive to tamoxifen in the presence of Insulin:** To further evaluate the effect of T-bet mediated changes in estrogen response on sensitivity to anti-estrogens, we examined tamoxifen sensitivity of parental and T-bet overexpressing cells. Both cell types were similarly sensitive to tamoxifen in the absence
of Insulin (Figure 4). T-bet overexpressing cells were more responsive to Insulin-mediated growth stimulation and consequently, were less sensitive to tamoxifen. Thus, it appears that Insulin not only induces T-bet expression but also influences T-bet function as evident from enhanced proliferation.

**Anti-estrogen resistant cells express higher levels of T-bet:** We used a clonal variant of MCF-7 cells and the same clone that acquired tamoxifen and Fulvestrant (ICI182,780) resistance (11) to determine whether there is a correlation between anti-estrogen resistance and T-bet expression. Both tamoxifen-resistant and ICI-resistant cells expressed higher levels of T-bet (Figure 5). FOXA1 expression was significantly reduced in these cells compared to parental cells. Thus, anti-estrogen resistance may involve selective upregulation of T-bet and loss of FOXA1 expression. Insulin may contribute to this process by increasing the expression and/or post-translational modification of T-bet.

**Ongoing studies:**

1) **Xenograft studies with MCF-7 cells under normal and experimentally induced diabetic condition:** We are waiting for tumors to develop in these animals for analysis.

2) **siRNA knockdown to T-bet in parental and tamoxifen resistant cells.** These studies are being performed to evaluate whether some of the observed effects of Insulin and tamoxifen resistance is dependent on T-bet.

**Key Research Accomplishments:**

- Luminal Type A breast cancers are characterized by a transcription factor signature comprised of GATA-3, ERα, and FOXA1.

- Treatment with Insulin induces the expression of T-bet and decreases GATA-3 expression in MCF-7 cells.

- Estrogen fails to induce XBP-1, a ERα:FOXA1:GATA-3 downstream target gene, in MCF-7 cells overexpressing T-bet. These results suggest T-bet mediated loss of Luminal Type A phenotype.

- Insulin confers tamoxifen resistance in those MCF-7 cells overexpressing T-Bet.

- Tamoxifen and Fulvestrant resistant cells overexpress T-bet and display disruption of ERα:FOXA1 and GATA-3 network.

- Disruption of the GATA-3:ERα:FOXA1 transcription network by T-Bet and Insulin provide a mechanism for progression of luminal type A to endocrine treatment resistance.

**Reportable Outcomes:** 2 abstracts published and one more is accepted for 2008 San Antonio Breast Cancer Symposium
Control of Luminal Type A Intrinsic Subtype Enriched Transcription Factor Network by Insulin: Implications of Diabetes on Breast Cancer Subtypes.

Control of Luminal Type (Lum) A Subtype Enriched Transcription Factor Network by Insulin: Implications of Diabetes on Breast Cancer Classification.

Conclusions: ERα, FOXA1 and GATA-3 constitute a key hormonal transcription factor network in Luminal type A breast cancer. Elevated levels of Insulin, as observed in diabetes, can disrupt this network and confer estrogen-independence through upregulation of T-bet, a transcription factor known to negatively regulate GATA-3 expression and/or activity. The above observations, which were generated through studies in vitro, are currently being evaluated in an in vivo model.

References:

**Appendices:**
Two abstracts.

**Supporting data:**
Figures
Control of luminal (LumA subtype enriched transcription factor network by insulin: Implications of diabetes on breast cancer classification. K. R. McCune, P. Bhat-Nakshatri, M. Thorat, S. Badve, H. Nakshatri; Indiana University School of Medicine, Indianapolis, IN

Background: LumA breast cancers express higher levels of ERα and are associated with better prognosis than LumB. A transcription factor network comprising GATA-3, FOXA1, and ERα is proposed to dictate hormone dependence of LumA cancers. Thus, signaling molecules that disrupt this network may force LumA cancer cells to acquire hormone independence or anti-estrogen (E2) resistance. T-bet (Thy1) is a well-established negative regulator of GATA-3. As the expression of some of the above factors is controlled by insulin, the objective of this study was to investigate whether elevated level of insulin, as in type II diabetes mellitus, alters gene expression patterns and anti-E2 sensitivity of LumA breast cancers by altering this network.

Methods: The effect of insulin on the expression of ERα, FOXA1, GATA-3, and T-bet was measured in ERα-positive MCF-7 cells by Western blotting. The effect of T-bet on E2-regulated gene expression was measured by qRT-PCR analysis of E2 inducible genes in parental MCF-7 and MCF-7 stably overexpressing T-bet (MCF-7-T-bet). BRDU-ELISA assay was used to measure the effect of E2, tamoxifen, and insulin on cell proliferation. The expression pattern of T-bet and its relation to ERα status in primary breast cancers were determined using Oncomine database.

Results: Insulin induced the expression of T-bet, which was partially reversed by E2. ERα and GATA-3 levels were reduced in MCF-7-T-bet cells compared to MCF-7 cells. E2-inducible expression of GREB-1 and Myb were lower in MCF-7-T-bet cells compared to MCF-7 cells, although basal expression of these genes was higher in MCF-7-T-bet cells. MCF-7-T-bet but not MCF-7 cells were resistant to tamoxifen in the presence of insulin. Although T-bet expression was observed predominantly in ERα-negative breast cancers, a subset of ERα-positive breast cancers overexpressed T-bet.

Conclusions: Insulin may change the gene expression pattern through T-bet-mediated disruption of GATA-3, ERα, and FOXA1 hormonal transcriptional network in LumA cancers. T-bet may serve as a marker to identify a subset of LumA cancers that have progressed to hormone independence.
28-1: CONTROL OF LUMINAL TYPE A INTRINSIC SUBTYPE UNPHRICHED TRANSCRIPTION FACTOR NETWORKS BY NSUNL IN IMPLICATIONS OF DIABETES ON BREAST CANCER SUBTYPES

Saketha K. Nakutahi,1,2 Karl R. McComb,1,3 Pournima Bhat-Nakutahi,1,3 Mangosh Joraat,1,3 and Sunil Badve1,3

Indiana University-Purdue University, Indianapolis, and Indiana University, Indianapolis.

Background: Breast cancer is classified into five intrinsic subtypes based on gene expression patterns: luminal type A, luminal type B, ErbB2+Her2+ positive, basal, and normal-like. Luminal type A and type B represent estrogen receptor (ER)-positive tumors with luminal type A expressing higher levels of ERs and is associated with better prognosis. Recent studies have identified a specific functional transcription factor network comprising GALA-3, FOXA1, and ERs in normal luminal cells as well as in luminal type A breast cancer that dictates their hormone dependence. Signaling molecules that may disrupt this network and force these cells to acquire hormone-independence are not known. T-bet (Th2-cell) has been described as a major negative regulator of GALA-3 activity. As the expression and activity of some of the above factors are controlled by insulin, the objective of this study was to investigate whether elevated levels of insulin, as evidenced in type II diabetes, alters gene expression pattern in luminal type A breast cancers by interrupting GALA-3, FOXA1, and ERs in normal luminal cells as well as in luminal type A breast cancer that dictates their hormone dependence.

Methods: The effect of insulin on the expression of ERα, FOXA1, GALA-3, and T-bet was measured in ERα-positive MCF-7 cells. Insulin was used at concentrations of 10−6, 10−7, and 10−8 M and compared with untreated control. The effect of T-bet on estrogen-regulated gene expression was measured by transient transfection assays and stable overexpression of T-bet in MCF-7 cells. Publicly available Omics database was used to determine the expression pattern of T-bet and its relation to ERα status in primary breast cancers. Immunohistochemistry was used to determine T-bet expression in normal breast and breast cancer.

Results: Insulin induced the expression of T-bet, which was partially reversed by nitrogen. In transient transfusion assays, T-bet reduced estrogen response elements (ERE)-driven reporter gene expression. ERα and GALA-3 levels were reduced in MCF-7 cells stably overexpressing T-bet suggesting that T-bet reduces GALA-3-dependent ERα expression. Estrogen-inducible expression of estrogen target gene GREB1 was lower in T-bet overexpressing cells compared to parental cells. Interestingly, ERα-negative breast cancers showed higher T-bet expression suggesting mutual interaction between ERα and T-bet.

Conclusion: Insulin may change the gene expression pattern through T-bet-mediated disruption of other cell-type-specific transcriptional networking including GALA-3, FOXA1, and ERα that dictates the phenotype of hormone-dependent luminal type A breast cancer. T-bet may serve as a marker to differentiate FOXA1+GAL-3+ breast cancers that may have progressed to hormone independence.

This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-17-1-0653.

28-2: FUNCTIONAL RELATIONSHIPS BETWEEN HER2 AND THE LEPRT SYSTEM IN BREAST CANCER

Eva UMMER

Temple University

Background: The obesity hormone leptin (Ob) has been implicated in tumorigenesis, especially in the development of breast cancer (BC). The hormone, adiponectin, and adiponectin receptors inside breast tumors have been well studied through the leptin receptor (ObR). Data obtained in HER2+31 cells engineered to coexpress ObR and the truncated HDER2 suggested that Ob can transactivate HER2 via ObR. To address this possible interaction, we studied whether simultaneous expression of Ob, ObR, and HER2 can occur in human BC. In cellular models, we studied if ObR and HER2 can physically interact and if activation of ObR is necessary in the transfer of HER2.

Material and Methods: The expression of Ob and ObR was evaluated by immunohistochemistry in 59 BCs (31 HER2-positive, 25 HER2-negative). Ob and ObR were classified as positive (at least 1+) or negative (at least 0). The relationships among Ob and ObR and the clinico-pathological factors, that is, grade (G1, G2, and G3), tumor size (cm), node involvement (positive or negative), vascular invasion (positive or negative), and ER and PR expression (positive or negative) were analyzed using the Chi square test. The immunohistochemical relationships between HER2 and HER2 were studied by western blotting, co-immunoprecipitation, and immunofluorescence/decoupled microscopy in MCF-7 cells that are sensitive to Ob and coexpression both receptors.

Results: Ob and ObR were coexpressed in 76% of BC and were coexpressed in all BCs (p<0.05) and normal tissues (p<0.006). The simultaneous expression of ObR and HER2 was found in 39% of BCs, but the Ob/ObR system was also in HER2-positive BCs. Ob, ObR, and coexpression of Ob and ObR did not correlate with HER2, grade, Vi, and ER/PR. Using MCF-7 cells, we found that the fraction of HER2 and HER2 are colocalized and can be found in one immunocomplex. We also demonstrated that 100 ng/ml of Ob activates HER2 tyrosine phosphorylation upon 1-3 min-1 turnover.

Conclusion: Ob and ObR are often coexpressed, and a subset of Ob/ObR-positive tumors exhibits concomitant expression of HER2. In BC cells, HER2 and Ob may physically interact and Ob can cross-activate HER2. Thus, high levels of Ob found in obese patients might lead to the activation of the Ob/ObR/HER2 signaling in BC contributing to the resistance of BC to anti-HER2 treatments.

This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-07-1-0003 and The Shabbir Health Research Organization.

28-3: Prolactin Promotes Mammary Tumorigenesis Secondary to Loss of p53

Kathleen A. Oker and Linda Schuler

University of Wisconsin, Madison

Multiple factors and pathways contribute to mammary tumorigenesis. Two factors that have separately been shown to increase breast cancer are the hormone prolactin (PRL) and the tumor suppressor p53. This study has begun to examine the interaction between these factors using two mouse models: p53 mice made congenic on the FVB/N background and the NBL-PRl transgenic mouse model which employs a non-hormonally regulated, mammary selective promoter to express PRL. In addition to the tumor suppressor p53, we are also examining the effects of increased PRL combined with loss of p53 cooperatively affect mammary tumorigene- sis in multiple ways. Tumor latency is decreased. The overall survival of the NBL- PRl-p53−/− recipients was 209 days compared to 247 days for the p53−/− recipients. In addition, the tumors appeared to be more aggressive. For the NBL-PRL-p53−/− tumors, 5/15 (33%) invaded into the peritoneal cavity. In contrast, the tumors were not observed in the p53−/− tumors 69% (9/14); all were confined to the mammary fat pad. However, NBL-PRL-p53−/− and p53−/− tumors were similar histologically. Both were highly anaplastic and were identified as either carcinomas or spindle cell tumors or adenocarcinomas, indicating that loss of p53 appears to alter the tumor histology. Thus, it appears that PRL and p53 pathways interact to promote breast cancer by decreasing latency and increasing aggressiveness. Further studies are being done to examine the contribution of genomic instability to this process.

This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-07-1-0007.

28-4: Inhibition of Estrogen-Induced Growth of Breast Cancer Cells by Modulating in situ Oxidant Levels

Dessalea Reya, Quionela Fedi, Victor Okah, and Nana-Aisha Garbu

Florida International University

The purpose of the our BCRP-funded proposal (HCS100979) was to examine an unstudied and highly innovative concept in estrogen-induced carcinogenesis research, i.e., estrogen-induced mitochondrial ROS are involved in the promo- tion/progression of breast cancer through modulating signaling that controls the early G1 stage of the cell cycle. We previously reported that 17β-estradiol (E2)-induced mitochondrial (mt) reactive oxygen species (ROS) act in signaling molecular. Here we examined whether antioxidants, N-acetylcysteine and ebselen, overexpression of ROS lowering genes, such as catalase and silencing of mtTFA are able to induce cell growth arrest in the presence of estrogen by analysis of the expression of early cell cycle biomarkers, cyclin D1 and PCNA, by real-time RT-PCR, the rate of DNA synthesis by BrDU incorporation, and different phases of cell cycle by flow cytometry. We also determined the morphology and behaviors of cells that overexpress mtTFA, catalase or silenced with mtTFA shRNA compared to those that do not express those genes normally expressed to ebselen. Our data revealed that E2-induced cell growth was reduced by antioxidants N-acetyl-L-cysteine (NAC), catalase, and the glutathione peroxidase mimetic ebselen. mtTFA shRNA transfection inhibited estrogen-induced proliferation of MCF-7 cells that is evident from the lower incorporation of BrDU in siRNA treated cells compared to wild-type cells in the presence of E2. We observed similar results by flow cytometry. In E2 treated MCF7 cells, the percentage of DNA content in S phase was 18% without E2 compared to 6.5% in siAtTA silenced MCF7 after 24 h. The FACS data not only confirms the results shown by the BrDU assay, it also shows that impairment of mitochondrial biogenesis prevents E2-induced entry of MCF7 cells into the S phase by arresting them in the G1/G0 phase. Both antioxidant treatment and downregulation of ROS prevented E2-induced expression of cyclin D1 and p21, markers of cell proliferation detected by real-time PCR. In cells overexpressed with adenovirus construct containing catalase that lowers oxidant production as well as mtTFA silenced cells using their shRNA, E2 was not able to produce any colony. Both antioxidants ebselen and N-acetylcysteine produced similar effects. It appears that the E2-dependent colony formation rate of MCF-7 cells is dependent on ROS or mitochondrial signaling. Since neither antioxidants nor mios-
Figure 1: Oncomine database search revealed overexpression of T-bet in a subset of ERα-positive breast cancers. Overall expression was significantly higher in ERα-negative breast cancer compared to ERα-positive breast cancers (p<0.000001).
Figure 2: A) Insulin induces T-bet expression in MCF-7 cells. Estrogen reduced Insulin-induced T-bet expression only at 8 hours time point. Cells were treated with 50 nM Insulin and/or 10^{-10} M estrogen. B). Insulin reduces GATA3 expression. Cells were treated with Insulin and/or estrogen for 24 hours as in A and lysates were analyzed for the expression of indicated proteins by Western blotting. C) Expression pattern of T-bet, GATA3 and FOXA1 in T47-D and BT-474 (ERα-positive) cells. Cells were treated with Insulin for 24 hours.
Figure 3: A) Generation of MCF-7 cells overexpressing T-bet. T-bet overexpressing cells were generated using a bicistronic retrovirus system. pQXIN corresponds to parental MCF-7 cells retrovirus vector alone. B) T-bet overexpression leads to loss of estrogen-inducible expression of XBP-1 but not Myb or Cyp19. Cells were treated with estrogen for indicated time and mRNAs corresponding to indicated genes were measured by quantitative reverse transcription polymerase chain reaction.
Figure 4: T-bet overexpressing cells are growth stimulated by Insulin and are less sensitive to tamoxifen. Cells were treated with indicated reagents for six days and bromodeoxyuridine incorporation-ELISA was used to measure the rate of cell proliferation. Proliferation rate of ethanol (vehicle for estrogen)-treated cells was normalized to one and relative proliferation is presented.
Figure 5: T-bet is overexpressed in tamoxifen (OHTR) and Fulvestrant-resistant (ICI-R) resistant derivatives of MCF-7 cells. ERE-Luc corresponds to parental MCF-7 cells but generated from a single clone expressing ERE-luciferase reporter gene (Ref. 11). Therefore, T-bet overexpression and loss of FOXA1 expression are acquired phenotypes during progression to anti-estrogen resistance.